#BIOSPAIN2025 | “Our decision to support this event is based on its ability to consolidate alliances and open new international opportunities”

As part of BIOSPAIN 2025, taking place from October 7 to 9 in Barcelona, we had the opportunity to speak with Gabriel Tallada, CEO of Net-Pharma Hub, which this year is participating as a Platinum Sponsor of the event. BIOSPAIN has established itself as one of the most important international gatherings in biotechnology, bringing together companies, startups, investors, and experts from across the sector to exchange knowledge and foster new collaboration opportunities.

In this interview, Tallada reflects on the key role of the collaborative economy within the biopharmaceutical sector, as well as the benefits and synergies that Net-Pharma Hub generates for the companies within its ecosystem. He also shares his perspective on internationalization, innovation, and the impact of collaborative hubs on the digital and sustainable transformation of the industry.

AseBio. What does it mean for Net-Pharma to be part of the collaborative economy ecosystem within the biopharmaceutical sector?

Gabriel Tallada. Being part of the collaborative economy ecosystem in the biopharmaceutical sector is essential for Net-Pharma Hub. This model allows us to share knowledge, infrastructure, and innovation, creating joint value that goes beyond what could be achieved individually.

AseBio. What do you consider to be the main benefits of belonging to a hub like Net-Pharma Hub for a company in the health or biotechnology sector?

Gabriel Tallada. The main benefits of belonging to a hub like Net-Pharma include immediate access to a network of companies with complementary expertise, reduced operating costs and development times, as well as greater visibility and scalability for projects.

AseBio. How does Net-Pharma Hub foster collaborative innovation among the companies that are part of its ecosystem?

Gabriel Tallada. Net-Pharma Hub drives collaborative innovation by providing shared workspaces, promoting inter-company projects, and offering strategic and regulatory services that accelerate innovation from its earliest stages.

AseBio. What types of synergies are generated in the Hub and how do they impact the development of business or scientific projects?

Gabriel Tallada. The Hub generates synergies such as joint product development, shared internationalization, and R&D alliances. These collaborations allow projects to advance faster, more efficiently, and with stronger technical support.

AseBio. In what way does the Net-Pharma Hub model contribute to the internationalization or scaling of startups in the biotech or pharmaceutical fields?

Gabriel Tallada. The Net-Pharma Hub model contributes to the internationalization and scaling of biotech and pharmaceutical startups through a network of international partners, global regulatory consulting, and strategic support in scaling processes, facilitating their entry into new markets with security and traction.

AseBio. Could you share a success story or notable collaboration that has emerged within the Hub?

Gabriel Tallada. A notable success story is our alliance with Barcelona & Partners, focused on attracting investment and developing projects in the life sciences sector. In addition, together with ICEX, we organize internationalization workshops to help our companies grow beyond our borders.

AseBio. What role do you think collaborative hubs like Net-Pharma Hub play in the digital and sustainable transformation of the biopharma sector in Spain?

Gabriel Tallada. Collaborative hubs like Net-Pharma Hub play a catalytic role in the digital and sustainable transformation of the biopharma sector in Spain. We facilitate the adoption of technologies, compliance with sustainability regulations, and connections with key players in the digital and environmental ecosystems.

AseBio. Net-Pharma Hub will be a sponsor of BIOSPAIN 2025. What are your expectations for this new edition and what motivated your decision to support this leading biotechnology event in Spain?

Gabriel Tallada. We expect BIOSPAIN 2025 to be an essential meeting point for the biotech sector, attracting talent, investors, and innovation. Our decision to support this event is based on its ability to consolidate alliances and open new international opportunities for our member companies.

The collaboration between AseBio and Net-Pharma Hub represents a significant milestone for the biopharmaceutical sector in Spain. This alliance not only strengthens the country’s innovation and development capacity but also positions Spain as a global benchmark in biotechnology. The synergy between both entities facilitates access to shared resources, promotes the creation of joint projects, and attracts international investment, thereby driving economic growth and scientific advancement in the biopharmaceutical field. This collaboration is a clear example of how the union of efforts can generate a positive and lasting impact on the industry and society.